Redmile Group

Redmile Group

$150,000,000 Venture capital (Series D)
TechCrunch , Forbes Tech , MedCity News

Breakout “CRISPR platform” company Mammoth Biosciences is officially a unicorn

MedCity News

Invitae to buy health records startup Ciitizen for $325M 

MedCity News

Second FDA clinical hold for Aprea cancer drug cites safety data in another study

Pulse 2.0

Xeris Pharmaceuticals Shares Increase Over 20% Pre-Market: Why It Happened

Pulse 2.0

Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer

neurons.AI

Protein discovery and development platform AbSci files for a $100 million IPO

€75,000,000 Venture capital (Series A)
Sifted

Round size surge gives France largest-ever Series A

Acquisition
neurons.AI

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

$2,100,000,000
Pulse 2.0

One Medical (ONEM) Announces Deal To Buy Iora Health In $2.1 Billion Deal: Details

$133,000,000 Venture capital (Series E)
Pulse 2.0

Diabetes Reversal Leader Company Virta Health Raises $133 Million

$53,000,000 Venture capital (Series C)
neurons.AI , neurons.AI

Ceribell lands $53M for portable EEG that diagnoses hidden seizures in minutes

Pulse 2.0

Invitae Stock Price: $48 Target By Oppenheimer

Pulse 2.0

Invitae Stock Price Increased Over 10% Pre-Market: Why It Happened

GeekWire

Seattle biotech OncoResponse raises $40.6M to create antibody-based treatments for cancer

GeekWire

Biotech startup AbSci raises $125M for ‘Protein Printing’ tech; total funding up to $230M

TechCrunch

ElevateBio raises $525M to advance its cell and gene therapy technologies

GeekWire

AbSci acquires AI startup Denovium to boost synthetic biology platform

MedCity News

Augmedix goes public through reverse merger

$65,000,000 Venture capital (Series E)
GeekWire

Synthetic biology startup AbSci raises $65M to expand ‘Protein Printing’ tech

MedCity News

FDA green-lights second RET inhibitor, this time from Blueprint Medicines